How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,365 results for

Medication Causes of Dyspepsia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. A New Approach to the Management of Uninvestigated Dyspepsia in Primary Care Full Text available with Trip Pro

A New Approach to the Management of Uninvestigated Dyspepsia in Primary Care The prevalence of dyspepsia in the general population worldwide is very high (20-40%). Upper abdominal complaints are one of the most common cause of patients' visits to primary care settings. Making an accurate etiological diagnosis of dyspepsia is difficult, but is an important challenge and goal for every doctor in primary care practice. Clinical guidelines have standards for gastroesophageal reflux disease (...) dyspeptic patients underwent abdominal ultrasound, and 1000 dyspeptic patients from the same group upper endoscopy.. In this approach diagnostic evaluation of dyspepsia includes: abdominal ultrasonography as a first line obligatory routine method and the exact estimation of nutritional condition.Abdominal ultrasound, physical examination and BMI control have significant value in the diagnostic evaluation of dyspepsia. The therapeutic approach includes, besides general standards (acid suppressive drugs

2015 Medical Archives

82. Sasang constitution affects the prevalence of functional dyspepsia. Full Text available with Trip Pro

Sasang constitution affects the prevalence of functional dyspepsia. Functional dyspepsia (FD), which is a very common disorder worldwide, is known to be caused by multiple factors including environmental and genetic factors. Sasang constitutional medicine (SCM) is a component of traditional Korean medicine that emphasizes inherited characteristics of the physical and psychological patterns of a patient. This study investigated whether the prevalence of FD differs depending on Sasang

2015 BMC Complementary and Alternative Medicine

83. Non-steroidal anti-inflammatory drugs are effective for dysmenorrhoea

for dysmenorrhoea, though women using them need to be aware of the significant overall risk that they may cause adverse effects, such as indigestion, headaches or drowsiness. There is insufficient evidence to indicate whether any individual NSAID is more effective or safer than others. It appears NSAIDs are more effective than paracetamol, though there were only 3 relevant studies. Nineteen different types of cox-1 NSAIDs were evaluated in the included studies. Caveat The included studies used a wide variety (...) . Research has shown women with dysmenorrhoea have high levels of prostaglandins, hormones known to cause cramping abdominal pain. NSAIDs are drugs which act by blocking prostaglandin production. Cochrane Systematic Review Marjoribanks J et al. Non-steroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Reviews 2010, Issue 1. Article No. CD001751. DOI: 10.1002/14651858.CD001751.pub2. This review contains 73 studies involving 5156 participants. PEARLS 236 March 2010, written by Brian R McAvoy

2011 Cochrane PEARLS

84. Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia. (Abstract)

Why dyspepsia can occur without organic disease: pathogenesis and management of functional dyspepsia. Functional dyspepsia (FD), one of the most common conditions in medicine, is a gastrointestinal disorder in which the patient suffers from chronic dyspeptic symptoms such as epigastralgia and a heavy feeling in the stomach despite the absence of organic disease. Elucidating the pathogenesis of FD means answering the question, "Why do symptoms occur?" The factors contributing to symptom (...) , in the primary care setting, the treatment of FD has focused on local gastric factors, including abnormal gastric acid secretion, abnormal gastric motility, and H. pylori infection. Acid secretion inhibitors and prokinetics have been commonly used, and H. pylori eradication therapy has been carried out, but the effectiveness of drug therapy has been limited.

2012 Journal of gastroenterology

85. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02) Full Text available with Trip Pro

Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02) Rikkunshito, an herbal medicine, is widely prescribed in Japan for the treatment of anorexia and functional dyspepsia, and has been reported to recover reductions in food intake caused by cisplatin. We investigated whether rikkunshito could improve (...) chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients treated with cisplatin.Patients with uterine cervical or corpus cancer who were to receive cisplatin (50 mg/m² day 1) and paclitaxel (135 mg/m² day 0) as first-line chemotherapy were randomly assigned to the rikkunshito group receiving oral administration on days 0-13 with standard antiemetics, or the control group receiving antiemetics only. The primary endpoint was the rate of complete control (CC: no emesis, no rescue medication

2017 Journal of gynecologic oncology Controlled trial quality: uncertain

86. Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment

Volunteers: No Criteria Inclusion Criteria: Participants with non-ulcer functional dyspepsia or scarred peptic ulcer disease Ability and willingness to participate in the study and to sign and give informed consent confirmed H. pylori infection Exclusion Criteria: Previous H. pylori eradication therapy Less than 18 years old With history of H. pylori infection treatment With previous gastric surgery Major systemic diseases Pregnancy or lactation Allergy to any of the study drugs Administration (...) ) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Hong Lu, MD, Shanghai Jiao Tong University School of Medicine: Helicobacter pylori Bismuth quadruple therapy Tailored therapy Empiric therapy clarithromycin susceptibility Additional relevant MeSH terms: Layout table for MeSH terms Helicobacter Infections Gram-Negative Bacterial Infections Bacterial

2016 Clinical Trials

87. Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea

tract and are not caused by structural or biochemical abnormalities. As a result, medical tests- such as blood tests and endoscopic exams- have essentially normal/negative (non-disease) results. More than 20 functional GI disorders have been identified. They can affect any part of the GI tract. One of the most common functional disorders is nausea and dyspepsia (pain or discomfort in the upper abdominal area, feeling of fullness, bloating). Any chronic illness, including functional nausea (...) /treatment Phase Functional Nausea Other: Acupressure Other: Placebo-band Drug: Iberogast Other: Placebo-drops Not Applicable Detailed Description: Functional gastrointestinal disorders are common disorders that are characterized by persistent and recurring GI symptoms. These occur as a result of abnormal functioning of the GI tract and are not caused by structural or biochemical abnormalities. As a result, medical tests- such as blood tests and endoscopic exams- have essentially normal/negative (non

2016 Clinical Trials

88. High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

Collaborator: Takeda Pharmaceuticals International, Inc. Information provided by (Responsible Party): Monthira Maneerattanaporn, Mahidol University Study Details Study Description Go to Brief Summary: The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional dyspepsia patients. Condition or disease Intervention/treatment Phase Dyspepsia Helicobacter-associated Gastritis Stomach (...) in Functional Dyspepsia Patients Study Start Date : May 2013 Actual Primary Completion Date : August 2014 Actual Study Completion Date : September 2014 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Sequential therapy (ST) 10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d

2013 Clinical Trials

89. Proton Pump Inhibitors: Indigestion for nephrologists!

Proton Pump Inhibitors: Indigestion for nephrologists! Renal Fellow Network: Proton Pump Inhibitors: Indigestion for nephrologists! | | | | | Monday, February 8, 2016 Proton Pump Inhibitors: Indigestion for nephrologists! Proton pump inhibitors (PPIs) are one of the most commonly prescribed medications, mostly because of their efficacy and their favorable safety profile. However, it has been that between 25% and 70% of these prescriptions do not have an appropriate indication. The of PPI use (...) that prescription rates in this population are several times greater than in the general population. It is speculated that the overuse in patients with CKD may be related to polypharmacy, co-morbidities, or the involvement of many physicians in their care. In 1992, a sentinel identified the PPI omeprazole, as a possible cause of acute interstitial nephritis (AIN) in an elderly woman. Since that time, a growing body of literature suggests that this class of drugs may be linked to AKI, which can potentially lead

2016 Renal Fellow Network

90. Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy

for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy Resource links provided by the National Library of Medicine available for: resources: Interventions Go to Intervention Details: Drug: Oral Domperidone 10 mg of oral domperidone administered (four times a day) for two weeks Drug: Oral Domperidone Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion Drug: Oral Domperidone Increased to 30 mg four times a day at the Investigator's discretion Eligibility (...) Criteria Inclusion Criteria: Male or female Age 18 and older Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation refractory to standard therapy. Patients must have a comprehensive evaluation (physical exam and also may include EGD, gastric emptying study, as clinically necessary) to eliminate other

2015 Clinical Trials

91. Primary Care Corner with Geoffrey Modest MD: Functional Dyspepsia

and occurring at least weekly, and no organic explanation But, symptoms above to not reliably distinguish “functional” from organic cause: <10% with dyspepsia have a peptic ulcer, <1% gastroesophageal cancer, and >70% have functional dyspepsia as determined by EGD (i.e., nothing found) One other overlapping diagnosis is GERD, but more than 50% of patients meeting functional dyspepsia criteria with symptoms of heartburn and regurgitation had normal 48-hour pH studies, and in these patients, heartburn (...) (0.8% in a large meta-analysis — Gastroenterology 2006; 131: 390) Frequency of celiac disease, the great imitator, is not increased in those with dyspepsia In terms of routine testing: they recommend H pylori stool antigen or breath test when the prevalence of H pylori infection is at least 10%, or, if you don’t know prevalence, it is still reasonable There is a trend to distinguish 2 types of functional dyspepsia, with the hope that there may be different effective therapies: Epigastric pain

2015 Evidence-Based Medicine blog

92. Fixation error can be deadly in medicine

at the site of John’s prosthetic aortic valve. This had been the culprit all along. The fluid backed up to the liver, and the ensuing congestion caused symptoms and signs that almost exactly mimicked gallstones. Fixation error can be deadly in medicine, as well as in other industries. On December 29, 1972, the experienced crew of an Eastern Air Lines flight en route from New York City to Miami became preoccupied with a landing gear problem. While resting in a holding pattern on autopilot, the crew became (...) Fixation error can be deadly in medicine Fixation error can be deadly in medicine Fixation error can be deadly in medicine | | February 26, 2018 145 Shares John Grover is a nice guy. He’s fifty-five, short, a little chubby, and he has a neatly trimmed red beard. He’s the kind of guy whose eyes light up the moment you walk into the room; The kind of guy who remembers your kids’ names, their ages, and their interests. I’d met him a few times before. He’d come in once to refill his blood pressure

2018 KevinMD blog

93. Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia

relevant functional gastrointestinal disorders (FGIDs) among general population. Rome III criteria defined functional dyspepsia as the presence of symptoms from the gastroduodenal region (early satiation, postprandial fullness, epigastric pain or burning) in the absence of any organic, systemic or metabolic disease that is likely to explain the symptoms. Etiological causes are still unclear, and the pathophysiological mechanisms still largely unknown. Besides, Helicobacter pylori infection is often (...) Official Title: Evaluation of Gastric Emptying Time, Gastric Electrical Activity and Gastrointestinal Peptides to Identify Dyspeptic Patients With Epigastric Pain Syndrome From Those With Postprandial Distress Syndrome According to the Rome III Proposed Subdivision of Functional Dyspepsia Study Start Date : April 2014 Actual Primary Completion Date : November 2014 Actual Study Completion Date : June 2015 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go

2014 Clinical Trials

94. Effect of Genetic Association With Functional Dyspepsia and Mood Disorders

or medications that affect motility in past 4 weeks Organic disease as cause of dyspepsia (for subjects with dyspeptic symptom) Additional to healthy volunteer • Any gastrointestinal symptoms (including acid regurgitation, heartburn, epigastric pain, bloating sensation, constipation, abdominal pain, diarrhea) in the past 4 weeks Additional to FD patient Frequent (once or more per week) acid reflux or heartburn symptoms Helicobacter pylori (Hp) infection Contacts and Locations Go to Information from (...) Association With Functional Dyspepsia and Mood Disorders Study Start Date : August 2012 Estimated Primary Completion Date : December 2017 Estimated Study Completion Date : December 2017 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Group/Cohort •FDR-Relatives of FD patients Relatives of FD patients. Patients may bring at most two FDRs to participate in this study. Up to 20 ml of fasting blood sample will be collected Serology test of Hp status

2014 Clinical Trials

95. Study of Motilitone to Treat Functional Dyspepsia

of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Motilitone 30mg Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks. Drug: Motilitone 30mg 30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks Placebo Comparator: Placebo Placebo (same formulation as Motilitone but without the active ingredients) will be administered (...) Summary: This study is to evaluate efficacy of the investigational drug Motilitone at 90 mg in patients with Functional Dyspepsia as measured by change in maximum tolerated volume and aggregate symptom score on the nutrient drink test. Condition or disease Intervention/treatment Phase Dyspepsia Drug: Motilitone 30mg Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 42 participants Allocation: Randomized

2014 Clinical Trials

96. Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method

, Samsung Medical Center. Recruitment status was: Not yet recruiting First Posted : May 30, 2014 Last Update Posted : November 25, 2014 Sponsor: Samsung Medical Center Information provided by (Responsible Party): Poong-Lyul Rhee, Samsung Medical Center Study Details Study Description Go to Brief Summary: Functional dyspepsia (FD) is a disorder characterized by chronic or recurrent upper abdominal pain or discomfort in the absence of a specific structural cause.1 Several mechanisms have been suggested (...) motilitone 90 mg daily, motilitone 180 mg daily or placebo in a double blinded manner. After 2 weeks of treatment, patients undergo gastric MRI. The primary endpoint is gastric emptying rate. The secondary endpoints are gastric accommodation and symptom improvement. Condition or disease Intervention/treatment Phase Dyspepsia Drug: Placebo Drug: motilitone Not Applicable Detailed Description: Same as above Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

2014 Clinical Trials

97. SSRI Study for Functional Dyspepsia (SS)

Organic disease as cause of dyspepsia H. pylori infection Use of PPI or NSAID in the past 4 weeks Pregnancy Known hypersensitivity to SSRI Unable to read Chinese or illiterate Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02153567 Locations Layout (...) , the correlation between plasma serotonin level in FD patients treated with SSRI is lacking in these studies. Indication: Functional dyspepsia patients Study center(s): Prince of Wales Hospital, Hong Kong Aims : To evaluate the effect of SSRI treatment on change of plasma serotonin level To evaluate the relationship between dyspeptic symptom and change of plasma serotonin level Study medication: Escitalopram (Lexapro) 5mg daily for first 2 weeks, and then 10 mg daily for 8 weeks versus Placebo for 10 weeks

2014 Clinical Trials

98. Days lost due to disability of diclofenac-induced adverse drug reactions Full Text available with Trip Pro

renal failure (0.012) Steven-Johnson syndrome (0.013) even though few cases were reported.Diclofenac has a complex adverse drug profile. Around 34 types of reactions were reported. Diclofenac was widely prescribed because of the experiential belief of comparative safety with other NSAIDs. The study shows the importance of pharmacovigilance even on the most prescribed medicine. Most disabling ADR for the study population was peptic ulcer with or without perforation. YLD or DLD are useful measures (...) Days lost due to disability of diclofenac-induced adverse drug reactions Disability Adjusted Life Years (DALY) is a widely used measure to quantify the burden of diseases or illness. DALYs for a disease is calculated as the sum of the Years of Life Lost (YLL) due to premature mortality in the population and the equivalent healthy Years Lost due to Disability (YLD). The only difference from the YLD and Days Lost due to Disability (DLD) calculation is that instead of considering the duration

2012 Pharmacy Practice

99. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID

efficacy of anti- platelet treatment because of a drugdrug interaction. Patients without these risk factors for GI bleeding receive little if any absolute risk reduction from a PPI, and the risk/benefit bal- ance would seem to favor use of antiplatelet therapy without concomitant PPI. The reduction of GI symptoms by PPIs (i.e., treatment of dyspepsia) may also prevent patients from dis- continuing their antiplatelet treatment. The discontinuation of antiplatelet therapy in patients with GI bleeding (...) exclusively by the ACCF without commercial support. Writing committee members volunteered their time to this effort. Conference calls of the writing committee were confidential and attended only by committee members. 1. In TRodu CTIon The potential benefits of antiplatelet therapy for atherosclerotic cardiovascular (CV) disease have been amply demonstrated over the past 2 decades, especially with regard to the role of thienopyridine drugs in preventing stent thrombosis. How- ever, antiplatelet agents

2010 American College of Gastroenterology

100. Dyspepsia. (Abstract)

Dyspepsia. Dyspepsia affects up to 40% of the general population and significantly reduces quality of life. A small proportion of patients have peptic ulcer disease as cause and this can be treated empirically with Helicobacter pylori eradication therapy in those that are infected. Approximately 20% have gastro-oesophageal reflux disease and this can be effectively treated with proton pump inhibitor therapy. Patients who remain symptomatic may warrant an endoscopy, but most will have functional (...) dyspepsia. Treatment of functional dyspepsia remains a challenge.Recent large randomized trials suggest tricyclic antidepressant therapy may be effective in functional dyspepsia. A phase III randomized controlled trial reports that a new prokinetic, acotiamide, reduces dyspepsia symptoms in functional dyspepsia patients. There are also preliminary data that suggest buspirone, a drug that promotes gastric accommodation, is also effective in functional dyspepsia. There are also data to suggest

2013 Current opinion in gastroenterology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>